丁螺环酮治疗重症监护室患者焦虑的疗效分析

Efficacy analysis of buspirone in the treatment of patients with anxiety in intensive care unit

目的探讨丁螺环酮治疗重症监护室患者焦虑障碍的有效性和安全性。方法 122例重症监护室焦虑患者作为研究对象,采用随机数字表法随机分治疗组和对照组,各61例。治疗组给予丁螺环酮治疗,对照组给予阿普唑仑治疗。治疗1周后,比较两组患者的焦虑自评量表(SAS)和焦虑量表(HAMA)评分,记录两组患者治疗过程中的不良反应。结果治疗后治疗组SAS、HAMA评分(28.61±5.56)、(8.15±2.45)分明显低于治疗前的(64.49±7.40)、(30.52±8.56)分,差异具有统计学意义(P<0.05);对照组SAS、HAMA评分(29.05±5.69)、(8.36±2.46)分明显低于治疗前的(64.64±7.25)、(30.13±8.38)分,差异具有统计学意义(P<0.05);治疗后治疗组与对照组HAMA、SAS评分比较差异无统计学意义(P>0.05);治疗组治疗总有效率为98.4%,对照组治疗总有效率为96.7%,两组比较差异无统计学意义(P>0.05);治疗组不良反应发生率11.48%明显低于对照组的44.26%,差异具有统计学意义(P<0.05);两组治疗前后血尿便常规、凝血五项及肝肾功能比较差异无统计学意义(P>0.05)。结论丁螺环酮对于治疗重症监护室焦虑障碍的患者是安全的、有效的,值得临床推广。

Objective To investigate the effectiveness and safety of buspirone in the treatment of patients with anxiety in intensive care unit. Methods A total of 122 patients with anxiety in intensive care unit as study subjects were divided by random number table method into treatment group and control group, with 61 cases in each group. The treatment group was treated with buspirone, and the control group was treated with alprazolam. After 1 week of treatment, the self-rating anxiety scale（SAS） and Hamilton depression scale（HAMA） score between the two groups was compared, and the the adverse reactions during treatment was recorded. Results After treatment, the treatment group had obviously lower SAS and HAMA score as（28.61±5.56） and（8.15±2.45） points than（64.49±7.40） and（30.52±8.56） points before treatment, and their difference was statistically significant（P〈0.05）. The control group had obviously lower SAS and HAMA score as（29.05±5.69） and（8.36±2.46） points than（64.64±7.25） and（30.13±8.38） points before treatment, and their difference was statistically significant（P〈0.05）. After treatment, the treatment group and control group had no statistically significant difference in HAMA and SAS score（P〈0.05）. The treatment group had total treatment effective rate as 98.4%, which was 96.7% in the control group, and the difference was not statistically significant（P〈0.05）. The treatment group had obviously lower incidence of adverse reactions as 11.48% than 44.26% in the control group, and the difference was statistically significant（P〈0.05）. Both groups had no statistically significant difference in hematuria routine, blood coagulation, liver and kidney function before and after treatment（P〈0.05）. Conclusion Buspirone is safe and effective in treating patients with anxiety in intensive care unit, and it is worthy of clinical promotion.